Free Trial

Allakos (ALLK) Competitors

Allakos logo
$0.23 +0.00 (+1.69%)
Closing price 03/27/2025 04:00 PM Eastern
Extended Trading
$0.24 +0.00 (+0.13%)
As of 03/27/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALLK vs. CLYM, VIGL, ZURA, IVVD, SLS, ACOG, ANL, RANI, CABA, and VTGN

Should you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Climb Bio (CLYM), Vigil Neuroscience (VIGL), Zura Bio (ZURA), Invivyd (IVVD), SELLAS Life Sciences Group (SLS), Alpha Cognition (ACOG), Adlai Nortye (ANL), Rani Therapeutics (RANI), Cabaletta Bio (CABA), and Vistagen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry.

Allakos vs.

Climb Bio (NASDAQ:CLYM) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation.

In the previous week, Climb Bio had 7 more articles in the media than Allakos. MarketBeat recorded 9 mentions for Climb Bio and 2 mentions for Allakos. Allakos' average media sentiment score of 0.97 beat Climb Bio's score of 0.61 indicating that Allakos is being referred to more favorably in the news media.

Company Overall Sentiment
Climb Bio Positive
Allakos Positive

Climb Bio's return on equity of -42.21% beat Allakos' return on equity.

Company Net Margins Return on Equity Return on Assets
Climb BioN/A -42.21% -41.39%
Allakos N/A -140.87%-86.22%

Climb Bio has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Allakos has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 84.6% of Allakos shares are owned by institutional investors. 3.2% of Climb Bio shares are owned by insiders. Comparatively, 16.1% of Allakos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Climb Bio is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Climb BioN/AN/A-$35.12M-$2.13-0.60
AllakosN/AN/A-$185.70M-$1.32-0.18

Allakos received 181 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 58.84% of users gave Allakos an outperform vote.

CompanyUnderperformOutperform
Climb BioOutperform Votes
2
100.00%
Underperform Votes
No Votes
AllakosOutperform Votes
183
58.84%
Underperform Votes
128
41.16%

Climb Bio presently has a consensus price target of $10.00, indicating a potential upside of 687.40%. Allakos has a consensus price target of $2.00, indicating a potential upside of 752.15%. Given Allakos' higher probable upside, analysts plainly believe Allakos is more favorable than Climb Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Climb Bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
Allakos
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Allakos beats Climb Bio on 8 of the 15 factors compared between the two stocks.

Remove Ads
Get Allakos News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALLK vs. The Competition

MetricAllakosPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$21.17M$6.91B$5.64B$8.06B
Dividend YieldN/A2.73%4.56%4.02%
P/E Ratio-0.127.2024.5919.03
Price / SalesN/A225.82383.9393.17
Price / CashN/A65.6738.1634.64
Price / Book0.126.476.944.33
Net Income-$185.70M$141.90M$3.20B$247.06M
7 Day Performance-6.57%-3.02%-2.30%-0.53%
1 Month Performance-16.42%-4.63%3.07%-3.74%
1 Year Performance-81.66%-8.61%11.15%1.72%

Allakos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALLK
Allakos
4.6164 of 5 stars
$0.23
+1.7%
$2.00
+752.2%
-81.7%$21.17MN/A-0.12190Short Interest ↓
Positive News
CLYM
Climb Bio
3.0045 of 5 stars
$1.32
+1.5%
$10.00
+657.6%
N/A$88.74MN/A-0.629Earnings Report
News Coverage
VIGL
Vigil Neuroscience
3.9605 of 5 stars
$1.90
+0.5%
$16.25
+755.3%
-40.9%$88.68MN/A-0.9240Short Interest ↓
Positive News
ZURA
Zura Bio
2.1872 of 5 stars
$1.35
-2.9%
$15.80
+1,070.4%
-41.6%$88.15MN/A0.003Earnings Report
Analyst Forecast
News Coverage
IVVD
Invivyd
3.6039 of 5 stars
$0.72
-1.9%
$7.89
+989.4%
-84.8%$86.60M$25.38M-0.37100Analyst Forecast
Short Interest ↓
Gap Down
SLS
SELLAS Life Sciences Group
0.4053 of 5 stars
$1.23
+2.5%
N/A+12.6%$86.57M$1M-1.7810Earnings Report
Positive News
ACOG
Alpha Cognition
2.1387 of 5 stars
$5.33
-0.7%
$20.00
+275.2%
N/A$85.39MN/A-2.08N/AUpcoming Earnings
Analyst Upgrade
News Coverage
Positive News
Gap Up
ANL
Adlai Nortye
2.5021 of 5 stars
$2.30
+4.1%
$9.00
+291.3%
-74.8%$84.87M$5M0.00127Short Interest ↓
Positive News
Gap Up
RANI
Rani Therapeutics
3.035 of 5 stars
$1.47
-5.2%
$12.33
+739.0%
-55.8%$84.22MN/A-1.39110News Coverage
CABA
Cabaletta Bio
1.9625 of 5 stars
$1.72
-1.1%
$22.71
+1,220.6%
-90.6%$84.07MN/A-0.8050
VTGN
Vistagen Therapeutics
1.9758 of 5 stars
$2.91
+4.3%
N/A-42.5%$83.99M$698,000.00-1.9740
Remove Ads

Related Companies and Tools


This page (NASDAQ:ALLK) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners